Insights from 2023 ESMO Asia Annual Meeting
ESMO Asia 2023 Insights: "Final Results of the RATIONALE-305 Study - Tislelizumab + Chemo vs. Placebo + Chemo as 1L Treatment of Advanced GC/GEJC"
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Ken Kato
By
Insights from 2023 ESMO Asia Annual Meeting
FEATURING
Ken Kato
Login to view comments.
Click here to Login